Biopharmaceutical sequential statistical applications:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York u.a.
Dekker
1992
|
| Schriftenreihe: | Statistics
128 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XX, 348 S. |
| ISBN: | 0824786289 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV005724943 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 921103s1992 |||| 00||| engod | ||
| 020 | |a 0824786289 |9 0-8247-8628-9 | ||
| 035 | |a (OCoLC)25316620 | ||
| 035 | |a (DE-599)BVBBV005724943 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RM307.27 | |
| 082 | 0 | |a 615/.1901/072 |2 20 | |
| 245 | 1 | 0 | |a Biopharmaceutical sequential statistical applications |c ed. by Karl E. Peace |
| 264 | 1 | |a New York u.a. |b Dekker |c 1992 | |
| 300 | |a XX, 348 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Statistics |v 128 | |
| 650 | 4 | |a Analyse séquentielle | |
| 650 | 7 | |a Biofarmacie |2 gtt | |
| 650 | 2 | |a Biopharmacie | |
| 650 | 2 | |a Essais cliniques comme sujet | |
| 650 | 7 | |a Geneesmiddelen |2 gtt | |
| 650 | 4 | |a Médicaments - Essais cliniques - Méthodes statistiques | |
| 650 | 7 | |a Sequentiële analyse (statistiek) |2 gtt | |
| 650 | 7 | |a Statistische methoden |2 gtt | |
| 650 | 2 | |a Évaluation médicament | |
| 650 | 4 | |a Biopharmaceutics | |
| 650 | 4 | |a Clinical Trials as Topic | |
| 650 | 4 | |a Data Interpretation, Statistical | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drug Evaluation | |
| 650 | 4 | |a Drug Evaluation, Preclinical | |
| 650 | 4 | |a Drugs |x Testing |x Statistical methods | |
| 650 | 4 | |a Sequential analysis | |
| 650 | 0 | 7 | |a Sequentialanalyse |0 (DE-588)4128461-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinische Prüfung |0 (DE-588)4031192-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Bewertung |0 (DE-588)4006340-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Klinische Prüfung |0 (DE-588)4031192-2 |D s |
| 689 | 0 | 1 | |a Sequentialanalyse |0 (DE-588)4128461-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 1 | 1 | |a Bewertung |0 (DE-588)4006340-9 |D s |
| 689 | 1 | 2 | |a Sequentialanalyse |0 (DE-588)4128461-6 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Peace, Karl E. |e Sonstige |4 oth | |
| 830 | 0 | |a Statistics |v 128 |w (DE-604)BV000003265 |9 128 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003575955&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-003575955 | ||
Datensatz im Suchindex
| _version_ | 1804119909460869120 |
|---|---|
| adam_text | Titel: Biopharmaceutical sequential statistical applications
Autor: Peace, Karl E
Jahr: 1992
Contents Preface iii Contributors xvii I Sequential Methods 1 Overview of the Development of Sequential Procedures 3 Irving K. Hwang I. Introduction 3 II. Development of Sequential Methods 4 A. Classical Open and Closed Sequential Designs 4 B. Response Adaptive and Bayesian Approaches 5 C. Group Sequential Methods 6 D. Pseudosequential and Semi-Bayesian Approaches 10 in. Discussion 11 References 11 2 Practical Approaches to the Design and Conduct of Interim Analyses 19 Frank W. Rockhold and Gregory G. Enas I. Introduction 19 vii
viii Contents II. Monitoring Versus Interim Analysis 20 HI. Reasons for Interim Analyses 22 A. Trends in Aggregate Safety Data 22 B. Abandoning Lost Causes 22 C. Generation of New Hypotheses 22 D. Resource and Production Decisions 23 E. Overwhelming Efficacy in Life-Threatening Conditions 23 IV. Logistical Issues in the Interim Analysis Process 23 A. Timing and Speed of Analyses 24 B. Resources 25 C. Data Retrieval 25 D. Data Management 26 V. Interim Analysis Risk Management 26 VI. Dissemination of the Results of the Analysis 27 VII. Conclusion 28 References 28 3 Group Sequential Designs for Trials with Multiple Endpoints 29 Nancy L. Geller, Clare Gnecco, and Dei-In Tang I. Introduction 29 II. Methods 30 A. Bonferroni Correction 30 B. O’Brien’s Statistics 31 C. Use of O’Brien’s Statistics in Group Sequential Trials 32 III. Discussion 32 References 33 II Applications in Drug Screening 4 Statistical Design Considerations for Stagewise, Adaptive Dose Allocation in Dose-Response Studies 37 Paul I. Feder, David W, Hobson, Carl T. Olson, R. L. Joiner, and M. Claire Matthews I. Introduction 37 II. Stagewise, Adaptive Design Approach: Theory and Methods 41 A. Assumptions and Objectives 41 B. Design Process During the Experiment 43 C. Design Strategy Prior to the Experiment: Target Designs 44 D. A Priori Dose-Response Distributions and Past Data 47 E. Expected Information from the Target Designs 48 F. Sensitivity Analysis 51 G. SAS Computer Program to Carry Out the Stagewise, Adaptive Dose Allocation Procedures 56
Contents ix HI. Case Study of the Application of the Stagewise, Adaptive Dose Allocation Strategy 57 A. Background 58 B. Design Strategy Prior to the Experiment 58 C. Development of the A Priori Distribution 63 D. Choice of Doses for Stage 1 64 E. Intermediate Experimental Results: Choice of Doses for Stages 2 and 3 65 F. Sensitivity Analysis of Alternative Candidate Dose Allocations to Select Doses for Stage 4 68 IV. Additional Examples of the Application of the Stagewise, Adaptive Dose Allocation Strategy 75 A. Studies Where the A Priori Assumptions Were Contradicted 75 B. Studies Where the A Priori Assumptions Were Confirmed 77 C. Application of the Sensitivity Analysis Procedure for Study Planning 78 V. Discussion and Areas for Further Extension 79 Appendix 84 References 85 5 Stagewise, Group Sequential Experimental Designs for Comparisons of Quantal Response Levels Obtained with Candidate Treatment Regimens Versus Those with a Concurrent Control or a Specified Standard 87 Paul I. Feder, Carl T. Olson, David W. Hobson, M. Claire Matthews, and R. L. Joiner I. Introduction 87 II. Comparison of a Candidate Therapy Response Rate with a Specified Standard Rate (One-Sample Case) 91 A. Fixed-Sample-Size Plans 91 B. Fully Sequential Plans 93 C. Stagewise Plans 93 III. Comparison of a Candidate Therapy Response Rate with a Concurrent Standard Rate (Two-Sample Case) 102 IV. Example 105 V. Discussion 113 Appendix 114 References 115 III Applications in Anticancer Clinical Drug Development 6 Application of a Sequential Screening/Efficacy Design in an Advanced Colorectal Cancer Study 119 Samuel Wieand and Daniel J. Schaid
X Contents I. Background 119 n. Protocol 120 IQ. Monitoring and Data Collection 122 IV. Statistical Analyses 124 V. Conclusion 127 VI. Discussion 127 References 131 7 Group Sequential Methods in Multi-institutional Cancer Clinical Trials: A Case Study 133 Kathleen J. Propert and Kyungmann Kim I. Background 133 II. Study Design, Objectives, and Data Collection Procedures 135 m. Group Sequential Methods and Study Monitoring 138 IV. Results and Statistical Analyses 141 V. Discussion 147 References 152 8 Group Sequential Trial of Two Combination Chemotherapy Regimens in Good-Risk Patients with Advanced Germ Cell Tumors 155 Nancy L. Geller and George J. Bosl I. Background 155 II. Protocol 156 III. Monitoring and Data Collection 158 IV. Statistical Analyses 158 V. Conclusion 159 VI. Discussion 159 References 160 IV Applications in Antiviral Clinical Drug Development 9 Early Termination of a Trial of Azidothymidine for the Treatment of Patients with AIDS and AIDS-Related Complex 165 Anthony C. Segreti I. Background 165 II. Protocol 166 III. Monitoring and Data Collection 167 IV. Statistical Analyses 167 V. Conclusion 170 VI. Discussion 171 References 173
Contents XI 10 Interim Analysis of a Parallel Comparison Study of Dideoxycytidine Versus Azidothymidine in Patients with AIDS or Advanced AIDS-Related Complex 175 Amy H. Lin and Samuel V. Givens I. Background 175 A. AIDS 175 B. Dideoxycytidine 175 n. Protocol 176 A. Hypotheses and Sample Size Determination in Terms of Survival Rates 176 B. Interim Analyses and Group Sequential Design 178 C. Hypotheses in Terms of Relative Risk 178 D. Sample Size Determination in Terms of Relative Risk 179 E. Decision Rules 181 F. Data Safety Monitoring Board and Blinding 184 G. Censoring and Follow-up 184 ül. Monitoring and Data Collection 185 IV. Statistical Analyses 185 V. Conclusion 186 VI. Discussion 186 References 188 11 An Application of the Sequential Probability Ratio Test to an Unblinded Clinical Trial of Ganciclovir Versus No Treatment in the Prevention of CMV Pneumonia Following Bone Marrow Transplantation 189 Charles Du Mond I. Background 189 II. Protocol 190 m. Monitoring and Data Collection 191 IV. Statistical Analyses 192 V. Conclusion 194 VI. Discussion 194 References 197 V Applications in Cardiovascular Clinical Drug Development 12 Bayesian Methods in the Monitoring of Survival in Congestive Heart Failure 201 Nathan H. Enas, Federico Dies, Celedon R. Gonzales, and Donald A. Berry I. Background 201 A. Description of Congestive Heart Failure 201
xii Contents B. Congestive Heart Failure as a Health Problem and a Disease 202 C. Evaluation of New Treatments 203 D. Evaluation of Mortality 203 n. Protocol 204 A. Objectives and Statistical Hypothesis 204 B. Sample Size and Decision Rule 205 m. Monitoring and Data Collection 206 IV. Statistical Analyses 207 A. Covariate Information 210 B. Results 210 C. Sensitivity Analysis 211 V. Conclusion 214 VI. Discussion 214 Appendix 215 References 217 13 Interim Analysis in the Norwegian Multicenter Study 219 Irving K. Hwang and Bruce E. Rodda I. Introduction 219 II. The Norwegian Multicenter Study 220 III. The y-Family of a Spending Functions 221 IV. Retrospective Analyses Using the Group Sequential Approach 224 A. The Fixed-Event Approach 225 B. The Fixed-Time Approach 227 C. The Actual-Event Approach 229 V. Discussion 230 References 232 14 Interim Analysis of the Helsinki Heart Study Primary Prevention Trial 235 Harry Haber I. Background 235 II. Protocol 236 III. Monitoring and Data Collection 237 IV. Statistical Analysis 238 V. Conclusion 241 VI. Discussion 241 References 242 15 Plans for the Enalapril Post-MI Trial (CONSENSUS II) 245 Steven M. Snapinn I. Background 245 II. Protocol 246
Contents xiii HI. Monitoring and Data Collection 247 IV. Sequential Analysis Plans 248 V. Conclusion 251 References 251 VI Applications in Gastrointestinal Clinical Drug Development 16 Early Termination of Two Trials of Misoprostol in the Prevention of NSAID-Induced Gastric Ulceration 255 Karl E. Peace I. Background 255 H. Rationale 255 in. Protocols 259 A. Objectives 259 B. Admission Criteria 259 C. Efficacy Parameters 260 D. Sample Size Determination 260 E. Efficacy Endpoints 261 IV. Monitoring and Data Management 261 V. FDA Meeting 263 VI. Interim Analysis Plans 265 Vn. Conclusion and Final Remarks 267 References 269 Famotidine in Upper Gastrointestinal Hemorrhage 271 Karen L. Walton-Bowen I. Background 271 n. Protocol 272 A. Objectives 272 B. Study Design 273 C. Endpoints and Sample Size 274 D. The Decision Rule and Plans for Analysis 274 III. Monitoring and Data Collection 275 A. Data Review 275 B. The Interim Stage 276 C. The Final Analysis Stage 277 IV. Statistical Analyses 277 A. Interim Analysis After 500 Patients 277 B. Final Analysis After 1000 Patients 278 V. Conclusion 280 VI. Discussion 280 References 281
xiv Contents VII Applications in Other Areas of Clinical Research 18 Sample Size Reestimation in Clinical Trials 285 Weichung Joseph Shih I. Introduction 285 II. Stein’s Procedure 287 A. One-Sample Case 287 B. Two-Sample Case 287 C. Example 289 HI. Two-Sample Normal Case Without Unblinding 289 A. Procedure 290 B. Simulation Results 293 C. Example 294 IV. Two-Sample Binary Case Without Unblinding 294 V. Discussion 299 References 300 19 Interim Analysis in the Development of an Anti-Inflammatory Agent: Sample Size Reestimation and Conditional Power Analysis 303 Ronald Pedersen and Robert R. Starbuck I. Background 303 n. Protocol 303 A. Original Plan 303 B. Modified Approach—Rationale 304 C. Final Interim Analysis Plan 305 III. Monitoring and Data Collection 305 IV. Statistical Methods and Results 307 A. Sample Size Reestimation 307 B. Conditional Power Calculation [Following Ware (1988)] 308 C. Estimating the Covariance Matrix 309 D. Treatment of Completed, Ongoing, and Unobserved Patients 310 E. Results 311 F. Disease Progression Rate Estimates 312 G. Conditional Power Calculation 313 V. Conclusion 313 VI. Discussion 314 References 314 20 Use of Interim Analyses to Design Further Studies in Analgesic Drug Preference 315 Albert J. Getson, Katherine H. Lipschutz, Robert L. Davis, and Balasamy Thiyagarajan I. Introduction 315
Contents xv II. Protocol 316 IQ. Monitoring and Data Collection 318 IV. Statistical Methodology 318 V. Statistical Analysis 319 VI. Conclusions 323 VII. Discussion 323 References 324 21 A Sequential Trial of Dantrolene in Human Malignant Hyperthermia 325 Paula K. Norwood I. Background 325 n. Statistical Analysis: Dantrolene Sodium IV Cooperative Study 327 A. Inclusion Criteria 327 B. Exclusion Criteria 327 C. Method of Analysis 327 III. Derivation of Method 328 IV. Results of the Trial 329 V. Summary 330 References 331 22 Randomized Play-the-Winner Designs and ECMO 333 Richard G. Cornell and David D. Cuthbertson I. Background 333 H. The Design and Results of the ECMO Study 334 A. Objective 334 B. Eligibility Criteria 335 C. Informed Consent 335 D. Randomization Procedure 335 E. Stopping Rule 336 F. Design Specification 336 G. Statistical Analysis 337 H. Results 337 HI. The Design of an RPW Trial for Hypothesis Testing 338 A. Objective 338 B. Decision Criteria 339 C. Rate of Adaptation 340 D. Design Specification 341 E. ECMO Examples 342 IV. Discussion 342 References 343 Index 345
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV005724943 |
| callnumber-first | R - Medicine |
| callnumber-label | RM307 |
| callnumber-raw | RM307.27 |
| callnumber-search | RM307.27 |
| callnumber-sort | RM 3307.27 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| ctrlnum | (OCoLC)25316620 (DE-599)BVBBV005724943 |
| dewey-full | 615/.1901/072 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.1901/072 |
| dewey-search | 615/.1901/072 |
| dewey-sort | 3615 41901 272 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02385nam a2200649 cb4500</leader><controlfield tag="001">BV005724943</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">921103s1992 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0824786289</subfield><subfield code="9">0-8247-8628-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)25316620</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV005724943</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM307.27</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1901/072</subfield><subfield code="2">20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biopharmaceutical sequential statistical applications</subfield><subfield code="c">ed. by Karl E. Peace</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York u.a.</subfield><subfield code="b">Dekker</subfield><subfield code="c">1992</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 348 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Statistics</subfield><subfield code="v">128</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Analyse séquentielle</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biofarmacie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biopharmacie</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Essais cliniques comme sujet</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geneesmiddelen</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments - Essais cliniques - Méthodes statistiques</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sequentiële analyse (statistiek)</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Statistische methoden</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Évaluation médicament</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biopharmaceutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Trials as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Data Interpretation, Statistical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation, Preclinical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield><subfield code="x">Statistical methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sequential analysis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Sequentialanalyse</subfield><subfield code="0">(DE-588)4128461-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bewertung</subfield><subfield code="0">(DE-588)4006340-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Sequentialanalyse</subfield><subfield code="0">(DE-588)4128461-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Bewertung</subfield><subfield code="0">(DE-588)4006340-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Sequentialanalyse</subfield><subfield code="0">(DE-588)4128461-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peace, Karl E.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Statistics</subfield><subfield code="v">128</subfield><subfield code="w">(DE-604)BV000003265</subfield><subfield code="9">128</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003575955&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-003575955</subfield></datafield></record></collection> |
| id | DE-604.BV005724943 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T16:33:41Z |
| institution | BVB |
| isbn | 0824786289 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-003575955 |
| oclc_num | 25316620 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XX, 348 S. |
| publishDate | 1992 |
| publishDateSearch | 1992 |
| publishDateSort | 1992 |
| publisher | Dekker |
| record_format | marc |
| series | Statistics |
| series2 | Statistics |
| spelling | Biopharmaceutical sequential statistical applications ed. by Karl E. Peace New York u.a. Dekker 1992 XX, 348 S. txt rdacontent n rdamedia nc rdacarrier Statistics 128 Analyse séquentielle Biofarmacie gtt Biopharmacie Essais cliniques comme sujet Geneesmiddelen gtt Médicaments - Essais cliniques - Méthodes statistiques Sequentiële analyse (statistiek) gtt Statistische methoden gtt Évaluation médicament Biopharmaceutics Clinical Trials as Topic Data Interpretation, Statistical Drug Design Drug Evaluation Drug Evaluation, Preclinical Drugs Testing Statistical methods Sequential analysis Sequentialanalyse (DE-588)4128461-6 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 gnd rswk-swf Bewertung (DE-588)4006340-9 gnd rswk-swf Arzneimittel (DE-588)4003115-9 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 s Sequentialanalyse (DE-588)4128461-6 s DE-604 Arzneimittel (DE-588)4003115-9 s Bewertung (DE-588)4006340-9 s Peace, Karl E. Sonstige oth Statistics 128 (DE-604)BV000003265 128 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003575955&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Biopharmaceutical sequential statistical applications Statistics Analyse séquentielle Biofarmacie gtt Biopharmacie Essais cliniques comme sujet Geneesmiddelen gtt Médicaments - Essais cliniques - Méthodes statistiques Sequentiële analyse (statistiek) gtt Statistische methoden gtt Évaluation médicament Biopharmaceutics Clinical Trials as Topic Data Interpretation, Statistical Drug Design Drug Evaluation Drug Evaluation, Preclinical Drugs Testing Statistical methods Sequential analysis Sequentialanalyse (DE-588)4128461-6 gnd Klinische Prüfung (DE-588)4031192-2 gnd Bewertung (DE-588)4006340-9 gnd Arzneimittel (DE-588)4003115-9 gnd |
| subject_GND | (DE-588)4128461-6 (DE-588)4031192-2 (DE-588)4006340-9 (DE-588)4003115-9 |
| title | Biopharmaceutical sequential statistical applications |
| title_auth | Biopharmaceutical sequential statistical applications |
| title_exact_search | Biopharmaceutical sequential statistical applications |
| title_full | Biopharmaceutical sequential statistical applications ed. by Karl E. Peace |
| title_fullStr | Biopharmaceutical sequential statistical applications ed. by Karl E. Peace |
| title_full_unstemmed | Biopharmaceutical sequential statistical applications ed. by Karl E. Peace |
| title_short | Biopharmaceutical sequential statistical applications |
| title_sort | biopharmaceutical sequential statistical applications |
| topic | Analyse séquentielle Biofarmacie gtt Biopharmacie Essais cliniques comme sujet Geneesmiddelen gtt Médicaments - Essais cliniques - Méthodes statistiques Sequentiële analyse (statistiek) gtt Statistische methoden gtt Évaluation médicament Biopharmaceutics Clinical Trials as Topic Data Interpretation, Statistical Drug Design Drug Evaluation Drug Evaluation, Preclinical Drugs Testing Statistical methods Sequential analysis Sequentialanalyse (DE-588)4128461-6 gnd Klinische Prüfung (DE-588)4031192-2 gnd Bewertung (DE-588)4006340-9 gnd Arzneimittel (DE-588)4003115-9 gnd |
| topic_facet | Analyse séquentielle Biofarmacie Biopharmacie Essais cliniques comme sujet Geneesmiddelen Médicaments - Essais cliniques - Méthodes statistiques Sequentiële analyse (statistiek) Statistische methoden Évaluation médicament Biopharmaceutics Clinical Trials as Topic Data Interpretation, Statistical Drug Design Drug Evaluation Drug Evaluation, Preclinical Drugs Testing Statistical methods Sequential analysis Sequentialanalyse Klinische Prüfung Bewertung Arzneimittel |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003575955&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003265 |
| work_keys_str_mv | AT peacekarle biopharmaceuticalsequentialstatisticalapplications |